Targets › IKZF1
3 programs from 3 companies in 14 trials: 6 Phase 1, 5 Phase 2, 3 Phase 3; Oncology, Immunology; next expected readout Dec 2026.
Transcription regulator of hematopoietic cell differentiation. Binds gamma-satellite DNA. Plays a role in the development of lymphocytes, B- and T-cells. (UniProt, Q13422)
Open in Phaseline: the race on IKZF1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | Golcadomide (CC-99282, BMS-986369) Cereblon E3 ligase modulator; dual IKZF1/IKZF3 degrader | CRBN, IKZF1, IKZF3 | Phase 3 | Large B-cell Lymphoma; Follicular Lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodgkin … | Apr 2027 |
| Alumis | Envudeucitinib (ESK-001) Oral PROTAC degrader of Ikaros (IKZF1) | IKZF1, TYK2 | Phase 3 | Plaque Psoriasis; SLE | Sep 2027 |
| Abdullah Khan | CC-92480 IKZF1/IKZF3 degrader | IKZF1, IKZF3 | Phase 1 | Recurrent Multiple Myeloma | Dec 2026 |
Plaque Psoriasis (2) SLE (1) Large B-cell Lymphoma (1) Follicular Lymphoma (1) Lymphoma, Follicular (1) Lymphoma, Non-Hodgkin (1) Lymphoma, B-Cell (1) Diffuse Large B-cell Lymphoma Refractory (1) Follicular Lymphoma Stage II (1) B-Cell Non-Hodgkin Lymphoma-Recurrent (1) Peripheral T Cells Lymphoma (PTCL) (1) Recurrent Mantle Cell Lymphoma (1)
mixed (2), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.